Drug combo could be tested for hepatitis C

Bristol-Myers Squibb is asking Gilead Sciences to conduct a Phase III trial combining Gilead's GS-7977 and Bristol's daclatasvir in patients with hepatitis C, after a midstage study delivered results that included a 100% response rate. www.courant.com/topic/sns-rt-bristolmyers-gilead-update-1l1e8gvh73-20120531,0,4620692.story